Hong Kong IPO: WuXi Biologics unit eyes up to US$520 million in biotech push WuXi XDC, a 60 per cent-owned unit of WuXi Biologics, could raise as much as US$520 million, including excess share ...

WuXi Biologics agreed to sell an overseas vaccine facility to Merck & Co. for half a billion dollars, a move that could strengthen the company’s cash flow and margins as it navigates global ...

A PAT roadmap should address data analysis, aggregation, visualization, and the smart utility of those data for greater process understanding.

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about $500 million, ahead of potential U.S. legislation that would restrict ...

SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it has been ...

WuXi Biologics (OTCPK:WXIBF) is reportedly selling its vaccine facility in Ireland to Merck (NYSE:MRK) as part of a previously announced plan to divest some of its assets. The China-based contract ...

WuXi Biologics' CEO Chris Chen has denied that the company’s sale of its less than four-year-old Ireland site is due to the threat of the US Biosecure Act, and said that the number of new ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener Wuxi Biologics ...

Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug ...

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop ...